H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $10.00. The company’s shares closed last Tuesday at $3.89.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.0% and a 43.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Arbutus Biopharma is a Moderate Buy with an average price target of $6.43, which is a 64.5% upside from current levels. In a report issued on March 5, Chardan Capital also reiterated a Buy rating on the stock with a $5.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.02 and a one-year low of $0.88. Currently, Arbutus Biopharma has an average volume of 3.24M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
